IQVIA Holdings Inc. (NYSE:IQV) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of IQVIA Holdings Inc. (NYSE:IQV) have received an average rating of “Moderate Buy” from the nineteen analysts that are presently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $259.13.

Several research firms recently commented on IQV. Robert W. Baird dropped their target price on IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a report on Friday, November 1st. Evercore ISI decreased their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. BTIG Research dropped their price target on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Argus upgraded shares of IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Finally, Barclays dropped their target price on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st.

Insiders Place Their Bets

In related news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On IQVIA

Several institutional investors have recently made changes to their positions in the stock. Versant Capital Management Inc boosted its holdings in IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after buying an additional 110 shares in the last quarter. Opal Wealth Advisors LLC purchased a new stake in shares of IQVIA during the 2nd quarter worth approximately $27,000. Capital Performance Advisors LLP purchased a new position in IQVIA in the 3rd quarter valued at approximately $27,000. Park Place Capital Corp acquired a new position in IQVIA during the third quarter worth $28,000. Finally, Itau Unibanco Holding S.A. purchased a new stake in IQVIA during the second quarter worth $29,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Down 1.0 %

Shares of IQV opened at $217.01 on Tuesday. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The stock has a market capitalization of $39.39 billion, a PE ratio of 28.48, a P/E/G ratio of 2.25 and a beta of 1.51. The company’s 50-day simple moving average is $231.00 and its 200-day simple moving average is $229.16. IQVIA has a 1 year low of $191.45 and a 1 year high of $261.73.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.